Rigosertib Shows Promise in EB-Associated Skin Cancer
METHODOLOGY:
Researchers conducted an open-label, single-arm phase 2 study in Austria and the United States of five patients with advanced, treatment-refractory RDEB-SCC who had failed prior standard of care and were then treated with oral or intravenous (IV) rigosertib.
Participants (median age, 23 years) received either oral rigosertib (560 mg twice daily on days 1-21 of each 28-day cycle for 13 cycles) or IV rigosertib (1800 mg/24 h as a 72-h continuous infusion on days 1-3 of each 14-day cycle for eight cycles, then on days 1-3 of 28-day cycles until 1 year of treatment).
Two patients received IV treatment, two received oral treatment, and one received a combination of both.
The primary outcome was the objective response rate and safety. Quality of life was a secondary outcome.
TAKEAWAY:
Two patients achieved complete a compete response, and two others had partial responses. The fifth patient discontinued treatment early because of unrelated complications.
Rigosertib was generally well tolerated. Most adverse events were urinary-related (cystitis, hematuria) and manageable with dose adjustments or symptomatic treatment.
IN PRACTICE:
'These initial results indicate rigosertib as a promising drug therapy for RDEB-SCC where there is a substantial unmet need and no approved therapies,' the study authors wrote. The study, they noted, was the 'first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease.'
SOURCE:
The study was led by Martin Laimer, Department of Dermatology and Allergology and EB House Austria, University Hospital of the Paracelsus Medical University, Salzburg, Austria, and was published online on May 29 in British Journal of Dermatology .
LIMITATIONS:
Usefulness of imaging techniques in this study was limited, particularly because of the chronic inflammatory response in lesional skin that is inherent to RDEB.
DISCLOSURES:
The study was funded by Debra International through Debra Austria, Debra of America, Cure EB, and Debra UK. Laimer and three other authors reported receiving consulting fees and grants from Onconova Therapeutics, Inc. Two authors declared being employees of Onconova, which provided the study drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Elbows up talk 'nothing more than a slogan' says Sask. Premier Scott Moe
Premier Scott Moe says as trade talks between Canada and America hurtle towards an Aug. 1 deadline, taking an 'elbows up' approach is 'nothing more than a slogan.' The Saskatchewan premier made the comment on Wednesday at the conclusion of the Council of the Federation (COF) meeting, adding that the prospect of completely separating Canada from the economy of the United States is an 'unreasonable dream.' 'When someone says we need to move away from dealing with the United States, that can be true in part, but it certainly can't be true in all. They are our largest trading partner,' said Moe. But the premier also acknowledged the relationship between Canada and the U.S. will be changed, 'if not forever … for a long period of time' given combative rhetoric from U.S. President Donald Trump and his administration. Trump kicked off a trade war on March 4 when he announced 25 per cent tariffs on Canadian goods and a 10 per cent levy on Canadian energy. Over time, those tariffs have changed to now only apply to select goods that are non-Canada-United States-Mexico Agreement (CUSMA) compliant. Trump has indicated new tariffs are coming for Canada if a trade deal is not struck by Aug. 1. 'Our objective is not to reach a deal whatever it costs … We are pursuing a deal that will be in the best interest of Canadians.' said Prime Minister Mark Carney during the COF meeting. Moe said he's holding out hope that there will be zero tariffs come the start of next month, but noted efforts made by his government and others have already resulted in exemptions and lowered tariffs on certain goods, like oil and potash. Still, about five per cent of trade to the U.S. is subject to tariffs, Moe said, adding that CUSMA 'is working for Saskatchewan.' And while the tariffs are impacting Saskatchewan, the premier said 'it's maybe to a lesser degree' than elsewhere in Canada. That doesn't discount the larger impact of the tariffs, stressed Moe, saying the rhetoric and actions from the U.S. make this 'very much a time of uncertainty' as trade relationships are tarnished or reset. Moe noted that the 100 per cent import tariff imposed by China on canola in March is a direct result of Canada standing in lockstep with the U.S.'s own policy, which placed 25 per cent tariffs on aluminum and steel and 100 per cent tariffs on Chinese electric vehicles. 'The federal government continues to engage with China and we're supporting them every step of the way,' said the premier. A 'change in tone' As conversations continue between Ottawa and Saskatchewan to push forward energy and other projects, and as the feds continue to negotiate with Saskatchewan's two largest trade partners (China and the U.S.), Moe maintained that he was 'cautiously optimistic' about the Carney government. Moe acknowledged that this was a 'change in tone' from himself and spoke favourably of Bill C-5, which received royal assent on June 26 and was passed into law. It gives the federal government new powers to fast-track approvals for what it calls 'nation-building projects.' The bill has been opposed by Indigenous leaders and groups who have voiced concerns it might override their fundamental rights. The government amended the bill on June 18 so that it cannot override the Indian Act. Trump's threats of tariffs and annexation of Canada as the 51st state have spurred things like Bill C-5 as the Canadian government shifts priorities to large-scale domestic projects. The bill aims to 'strengthen Canada's autonomy, resilience and security,' according to a government website. At the same time, provincial and federal leaders have also been spurred to improve interprovincial trade in the face of tariffs. Though Moe started the COF inviting all provinces and territories to join the binding and interprovincial New West Partnership Trade Agreement (NWPTA), it seems to be that the fellow premiers have landed on expanding the Canada Free Trade Agreement (CFTA) instead. 'We'll continue to push all of the other provinces to expand the CFTA, to make it as close to a mirror image as we can to the New West Partnership,' he said. Having signed five memorandums of understanding since June 2 related to energy corridors, interprovincial trade and breaking down economic barriers, Moe said the renewed focus on improving trade between provinces and territories might be the only good to come out of Trump's threats. 'What you're seeing now is actual action in this space and I'd say it's high time.' — with files from The Canadian Press Related Saskatchewan's Scott Moe invites all Canadian premiers to join western trade agreement Saskatchewan Premier Scott Moe signs two more MOUs to open up interprovincial trade routes alsalloum@ The Regina Leader-Post has created an Afternoon Headlines newsletter that can be delivered daily to your inbox so you are up to date with the most vital news of the day. Click here to subscribe. With some online platforms blocking access to the journalism upon which you depend, our website is your destination for up-to-the-minute news, so make sure to bookmark and sign up for our newsletters so we can keep you informed. Click here to subscribe.
Yahoo
an hour ago
- Yahoo
New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship'
New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship' A new peer-reviewed study from researchers at Poland's Adam Mickiewicz University has found no evidence that wind turbine noise causes mental harm, putting to rest a persistent and unsubstantiated claim that clean energy projects may be harming our health. Medical Xpress reported that the study measured brainwave activity in 45 university students exposed to different sounds — including traffic, wind turbines, and silence — without revealing the sources. Participants described the turbine noise as white noise and did not report it as any more stressful than city traffic. The researchers also found no measurable differences in brain activity, nor any signs of psychological harm, across the various sound environments. "Although these results cannot be generalized, they support the concept that the interlinkage between exposure to wind turbine noise and human cognitive functioning is not a cause-and-effect relationship," the authors wrote in the study, published in the journal Humanities and Social Sciences Communications. While they acknowledged that their research is not definitive on long-term exposure, they concluded that "wind turbine syndrome" — the conspiracy theory suggesting these sounds cause cancer or mental illness — has no scientific basis. This is reassuring news for consumers and communities. Wind turbines are among the most cost-effective sources of clean energy and can offer great economic and health benefits. They reduce dependence on dirty energy sources like oil and gas, helping to curb rising health risks tied to air pollution. They can also help stabilize public energy grids and lower utility costs for homeowners. Plus, by reducing the amount of heat-trapping air pollution the energy industry generates, we're working toward a safer, cleaner future for all of us. Studies like this help cut through misinformation that could dampen public reception to clean power sources. "This interpretation is compatible with previous findings showing social contexts, such as socialization and misinformation, as a moderator of the interlinkage between wind turbine noise and human functioning," the study authors wrote. A discussion on Reddit shared similar viewpoints on the topic. "Colleague of mine [used] to do community engagement," one commenter said. "Received lots of calls about how the wind turbines were making people in the area sick. She had to tell them that the newly built turbines hadn't actually been switched on yet. Not saying some people weren't having a reaction though as the mind can be a powerful tool (look up the Nocebo effect)." Do you worry about air pollution in your town? All the time Often Only sometimes Never Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Medscape
an hour ago
- Medscape
Home BP Readings Often Beat Office Measurements
This transcript has been edited for clarity. Do you trust home blood pressure monitoring? You should, especially if it's done correctly. In fact, for many patients, it gives better data than occasional in-office readings, especially if they have white coat hypertension or masked hypertension. Here's how I interpret these data. First, I always ask if the device is validated and used properly. Upper arm cuffs are preferred, not wrist cuffs. Make sure they're sitting quietly for 5 minutes, back is supported, feet are flat, and no caffeine, smoking, or exercise within 30 minutes of the measurement. Then I look at the pattern, not one-off values. I ask patients to check twice in the morning and twice in the evening for 5 or 7 days. That gives me about 20-28 readings, which is enough to assess the true averages. I'm aiming for a home blood pressure goal that is slightly lower than the threshold used in the office, per the guidelines. If the average is above that consistently and the technique is solid, then I consider adjusting the therapy for that particular patient. Also, don't ignore variability. Wide swings may suggest nonadherence, autonomic dysfunction, or even secondary hypertension. If numbers are too low, especially with symptoms, it may be time to reduce the medications. Bottom line, home blood pressure data are reliable when done right. It often gives us a more accurate picture of real-world control than those seen in the office, and it should be part of routine hypertension management.
